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he protein kinase B-RAF is a human oncogene that
is mutated in 
 
 
 
70% of human melanomas and
transforms mouse melanocytes. Microphthalmia-
associated transcription factor (MITF) is an important me-
lanocyte differentiation and survival factor, but its role in
melanoma is unclear. In this study, we show that MITF ex-
pression is suppressed by oncogenic B-RAF in immortal-
ized mouse and primary human melanocytes. However,
low levels of MITF persist in human melanoma cells
harboring oncogenic B-RAF, suggesting that additional
T
 
mechanisms regulate its expression. MITF reexpression in
B-RAF–transformed melanocytes inhibits their prolifera-
tion. Furthermore, differentiation-inducing factors that el-
evate MITF expression in melanoma cells inhibit their pro-
liferation, but when MITF up-regulation is prevented by
RNA interference, proliferation is not inhibited. These
data suggest that MITF is an antiproliferation factor that is
down-regulated by B-RAF signaling and that this is a cru-
cial event for the progression of melanomas that harbor
oncogenic B-RAF.
 
Introduction
 
Melanocytes are pigmented skin cells that protect us from ultra-
violet radiation. The processes regulating melanocyte differenti-
ation are intensely studied because melanocytes are thought to
be the precursors of melanoma, a skin cancer whose incidence
is increasing in Western societies. A master regulator of me-
lanocyte differentiation is the microphthalmia-associated tran-
scription factor (MITF; Widlund and Fisher, 2003). Strikingly,
MITF levels are reduced in spontaneously transformed melano-
cytes (Selzer et al., 2002), and low MITF expression correlates
with poor prognosis in melanoma (Salti et al., 2000). MITF
regulation is complex. For example, the differentiation factor
 
 
 
-melanocyte–stimulating hormone strongly increases its ex-
pression in a cAMP and cAMP response element binding protein
(CREB) transcription factor–dependent manner (Bertolotto et
al., 1998). Another signaling module that regulates MITF is the
RAS–RAF–MEK–ERK signaling cascade, which acts down-
stream of the receptor tyrosine kinase cKIT to stimulate MITF
phosphorylation on serine 73 (S73) and enhances its transcrip-
tional activity (Hemesath et al., 1998). However, extracellular
regulated protein kinase (ERK)–mediated S73 phosphorylation
also targets MITF for ubiquitin-dependent degradation through
the proteasome pathway (Wu et al., 2000; Xu et al., 2000).
There are three 
 
RAS
 
 (
 
H-RAS
 
, 
 
K-RAS
 
, and 
 
N-RAS
 
) and
three 
 
RAF
 
 (
 
A-RAF
 
, 
 
B-RAF
 
, and 
 
C-RAF
 
) genes in humans. 
 
N-RAS
 
is mutated in 5–20% of melanomas, and 
 
B-RAF
 
 is mutated in
50–70% of melanomas (Davies et al., 2002). The most com-
mon mutation in B-RAF (
 
 
 
90%) is a glutamic acid for valine
substitution at position 600 (formally identified as V599; Well-
brock et al., 2004a), which produces a highly active kinase that
stimulates constitutive ERK signaling and stimulates mela-
noma cell proliferation and survival (Hingorani et al., 2003;
Karasarides et al., 2004).
In this study, we show that 
 
V600E
 
B-RAF triggers MITF deg-
radation in mouse and human melanocytes and that its reexpres-
sion inhibits proliferation. Furthermore, MITF up-regulation
suppresses melanoma cell proliferation. These data suggest that
high MITF levels are antiproliferative, and, therefore, its expres-
sion must be suppressed for transformation by oncogenic B-RAF.
 
Results and discussion
 
We previously described the generation of mouse melanocyte
lines expressing myc-tagged versions of 
 
WT
 
B-RAF (melan-a–
B-RAF) or 
 
V600E
 
B-RAF (melan-a–V600E [VE]; Wellbrock et
al., 2004b). We demonstrated that melanocytes expressing
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V600E
 
B-RAF show constitutive ERK signaling and proliferate in
a factor-independent manner (Wellbrock et al., 2004b). Impor-
tantly, cells expressing high or low levels of 
 
WT
 
B-RAF do not
have elevated ERK activity or grow in a factor-independent
manner, demonstrating that even high levels of 
 
WT
 
B-RAF
expression are not transforming. Melanocytes expressing
 
V600E
 
B-RAF (clone VE16; Fig. 1 A) display dramatically re-
duced dendricity and pigmentation, which is similar to the
morphology that is observed in melanocytes expressing onco-
genic RAS (
 
G12V
 
RAS) or constitutively active MAPK and ERK
kinase (MEK; MEK
 
EE
 
; Fig. 1 B). In contrast, clones expressing
low or high levels of 
 
WT
 
B-RAF (clones B2 and B9) have a pa-
rental phenotype (Fig. 1 B). The reduction in pigmentation and
dentricity that is induced by oncogenic B-RAF prompted us to
examine known regulators of melanocyte differentiation. Im-
portantly, we find that MITF is consistently down-regulated in
cell lines expressing 
 
V600E
 
B-RAF, 
 
G12V
 
RAS, and MEK
 
EE
 
, and
this loss correlates with constitutive ERK activation (Fig. 1 C).
Previous studies have shown that ERK phosphorylates
S73 of MITF, targeting it for degradation (Wu et al., 2000; Xu
et al., 2000), so we analyzed whether this mechanism underlies
MITF loss in our cell lines. Transiently expressed HA-tagged
MITF localizes to the nucleus of melan-a–VE cells (Fig. 2 A).
On SDS gels, it migrates as a single band whose mobility is in-
creased when the cells are treated with the MEK inhibitor
U0126 (Fig. 2 B); these effects were previously attributed to
ERK-dependent phosphorylation on S73 (Hemesath et al.,
1998). Accordingly, MITF in which S73 is mutated to alanine
(
 
S73A
 
MITF) comigrates with MITF in U0126-treated cells (Fig.
2 B). In melan-a–VE lines, ectopic MITF is expressed at low
levels, but these increase when the cells are treated with the pro-
teasome inhibitor MG132 (Fig. 2 C). This suggests that MITF is
degraded by the ubiquitin pathway after S73 phosphorylation by
ERK. However, when 
 
S73A
 
MITF is expressed, it also fails to ac-
cumulate unless the cells are treated with MG132 (Fig. 2 C).
This effect does not appear to be caused by mislocalization be-
cause 
 
S73A
 
MITF also resides in the nucleus (Fig. 2 A). Although
our data directly implicate the ubiquitin-mediated proteasome
pathway in MITF stability in melan-a–VE cells, MG132 did
not induce the accumulation of endogenous MITF in these
cells (Fig. 2 C, control), suggesting that additional mecha-
Figure 1. MITF expression is lost in B-RAF–transformed melanocytes.
(A) Western blot analysis of melan-a cells, a neo
R control line, 
WTB-RAF–
expressing  clones B2 and B9, and 
V600EB-RAF–expressing clone VE16
probed for myc-tagged B-RAF, total B-RAF, and ERK2. (B) Bright field im-
age of melan-a cells, neo
R controls, clones B2, B9, and VE16, and
G12VRAS- or MEK
EE-transformed melan-a cells under growing conditions.
(C) Western blot analysis of MITF, phosphorylated ERK (ppERK), and
ERK2 in melan-a cells, neo
R controls, 
WTB-RAF–expressing clones (B2 and
B9), 
V600EB-RAF–expressing clones (VE11, VE14, and VE16) and 
G12VRAS-
or MEK
EE-expressing cells.
Figure 2. Constitutive ERK activation triggers MITF down-regulation.
(A) Immunofluorescent analysis of recombinant HA-MITF and HA-
S73AMITF
in melan-a–VE16 cells using anti-MITF antibody C5. Nuclei are counter-
stained with DAPI. (B) Western blot analysis of transiently expressed HA-
MITF, HA-
S73AMITF, ppERK, and ERK2 in melan-a–VE16 cells that were
either untreated or treated with 10  M DMSO or U0126 for 2 h. Control
cells were transfected with empty vector, and HA-MITF proteins were de-
tected using anti-HA. (C) Western blot analysis of stably expressed HA-
MITF or HA-
S73AMITF in melan-a–VE16 cells untreated or treated with 30
 M MG132 for 8 h. HA-MITF proteins were detected using anti-MITF (C5).
Total ERK2 is used as a loading control. (D) RT-PCR of melanocyte-specific
MITF mRNA expression in parental melan-a cells and clones B2, VE11,
VE14, and VE16. GAPDH serves as a loading control. (E) RT-PCR analysis
of MITF expression in melan-a and melan-a–VE cells treated with 20  M
forskolin (FO) for the indicated times. GAPDH serves as a loading control.
(F) RT-PCR analysis of melanocyte-specific MITF mRNA in melan-a–VE cells
treated with 20  M forskolin for the indicated times in the presence of
10  M U0126 or DMSO (D) for a 10-min pretreatment. GAPDH serves as
a loading control. (G) Western blot analysis for phosphorylated CREB,
ppERK, and ERK2 in melan-a–VE cells treated with 10  M forskolin for
30 min, 10  M U0126 for a 10-min pretreatment, or DMSO. 
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nisms regulate MITF expression. RT-PCR analysis revealed
that MITF mRNA levels are significantly lower in melan-a–VE
cells than in parental or melan-a–B-RAF cells (Fig. 2 D), but the
cAMP-elevating agent forskolin still induces MITF expression
(Fig. 2 E). Importantly, forskolin-induced MITF expression
(Fig. 2 F) and CREB phosphorylation (Fig. 2 G) are not inhib-
ited by U0126, demonstrating that MEK–ERK signaling is not
required for MITF regulation by cAMP in these cells.
The aforementioned studies show that constitutive ERK
activity that is stimulated by 
 
V600E
 
B-RAF in melan-a cells is
associated with MITF down-regulation and phenotypic trans-
formation, suggesting that MITF loss is closely linked to me-
lanocyte transformation. Our data are consistent with previous
studies demonstrating that MITF degradation is stimulated by
ERK-dependent proteasomal degradation, although the mecha-
nism is unclear (Wu et al., 2000; Xu et al., 2000). However,
S73 phosphorylation is clearly not the only mechanism regulat-
ing MITF stability, and we show that a significant component
occurs through transcriptional control. A similar suppression
on the transcriptional level has been described in mouse mela-
nocytes that were transformed by oncogenic RAS or by basic
fibroblast growth factor overexpression (Halaban et al., 1996).
Importantly, in our cells, MITF down-regulation did not occur
by promoter silencing because it was still induced by cAMP.
To examine the biological consequences of MITF regula-
tion by B-RAF, we reexpressed MITF in melan-a–VE cells.
This caused a significant (73–84%) reduction in the number of
colonies that were formed by these cells (Fig. 3 A). To clarify
whether this effect was caused by inhibition of proliferation or
induction of apoptosis, we developed melan-a–VE cell lines
expressing an estrogen receptor (ER) version of MITF (ER-
MITF; Carreira et al., 2005) that can be regulated by 4-hydroxy-
tamoxifen (4-OHT) and developed a control cell line expressing
only the ER fragment. Both proteins are expressed at similar
levels (Fig. 3 B). ER-MITF activates the tyrosinase promoter in
a 4-OHT–dependent manner, whereas the ER fragment does
not (Fig. 3 C), demonstrating that ER-MITF is functional.
Critically, ER-MITF activation does not induce apoptosis in
melan-a–VE but significantly impairs its proliferation (38%
reduction, P 
 
  
 
0.0116; Fig. 3 D).
Because 
 
V600E
 
B-RAF mutations occur in 50–70% of hu-
man melanomas (Davies et al., 2002), we examined whether our
mouse cell studies were relevant to human melanocytes. First,
we analyzed the RAF–MEK–ERK pathway in primary normal
human melanocytes (NHMs). ERK inhibition by U0126 (Fig.
4 A) blocks DNA synthesis (Fig. 4 B), demonstrating that ERK
signaling is essential for NHM proliferation, so we examined
the contribution of individual RAF isoforms by RNA interfer-
ence (RNAi). Depletion of A-RAF from these cells did not af-
fect basal ERK activity (Fig. 4 C) or DNA synthesis (Fig. 4 D),
whereas depletion of B-RAF or C-RAF suppresses ERK activity
(Fig. 4 C) and significantly inhibits DNA synthesis (Fig. 4
D). Thus, A-RAF is not required for ERK-dependent melano-
cyte proliferation, whereas B- and C-RAF are both required.
This contrasts with observations in melanoma cells harboring
 
V600E
 
B-RAF in which only B-RAF is required for ERK activa-
tion but all three RAF kinases are required for proliferation
(Karasarides et al., 2004). The observation that B- and C-RAF
both contribute to ERK signaling and proliferation in NHM can
be explained by the fact that in melanocytes, these isoforms
stimulate nonredundant growth signals (Wellbrock et al., 2004a).
We have demonstrated that MEK–ERK signaling is es-
sential for NHM proliferation and that in melanoma cells, this
pathway is constitutively activated by 
 
V600E
 
B-RAF. Impor-
tantly, 
 
V600E
 
B-RAF also induces constitutive ERK activation
in NHM (Fig. 4 E), and MITF protein levels are suppressed
in 
 
 
 
92% of cells expressing 
 
V600E
 
B-RAF (Fig. 4. F and G).
 
WT
 
B-RAF does not significantly affect ERK (Fig. 4 E) or MITF
protein levels in NHM (Fig. 4, F and G).
Thus, MITF protein levels are significantly reduced in
melanocytes in which B-RAF–ERK signaling is elevated.
However, MITF is present in most melanoma cell lines ex-
pressing oncogenic B-RAF or RAS, albeit generally at reduced
Figure 3. MITF inhibits proliferation of B-RAF–transformed melanocytes.
(A) Melan-a–VE clones VE11 and VE16 were transfected with a Hygromycin
resistance plasmid plus empty vector or the MITF expression vector.
Western blot shows MITF expression 24 h after transfection in comparison
with endogenous MITF in melan-a cells. The cells were then selected for
Hygromycin resistance and stained for colonies 15 d after transfection.
Results are means from triplicate determinations with error bars to repre-
sent the SD. A representative stained cell image is shown to the right of the
graph. (B) Western blot analysis of stably expressed HA.ER and HA.ER-MITF
in melan-a–VE cells untreated or treated with 200 nM 4-hydroxy-tamoxifen
(4-OHT) for 24 h. HA.ER and HA.ER-MITF were revealed with the anti-HA
antibody. (C) Luciferase assay of melan-a–VE HA.ER or HA.ER-MITF cells
transfected with a tyrosinase promoter luciferase reporter. 24 h after trans-
fection, cells were untreated or treated with 200 nM 4-OHT for a further
24 h. Error bars represent SD from the mean. (D) Growth curve of melan-a–
VE HA.ER- or HA.ER-MITF–expressing cells in the absence or presence of
200 nM 4-OHT. Error bars represent SD from the mean. 
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levels compared with NHM (Fig. 5 A). Our data suggests that
MITF is antiproliferative and that one function of oncogenic
B-RAF is to suppress its expression to overcome its growth-
inhibitory activity. This model is supported by our observation
that MITF expression is reduced in NHM expressing 
 
V600E
 
B-RAF
(Fig. 4, F and G) and the finding that forskolin, which up-regu-
lates MITF (Fig. 5 B), also inhibits DNA synthesis in these
cells (Fig. 5 C). Forskolin also up-regulates MITF expression
in Colo829 and WM266-4 cells (Fig. 5 D, lanes 1, 2, 5, and 6)
and in two melanoma cell lines that express oncogenic B-RAF
(Davies et al., 2002), and this is accompanied by reduced pro-
liferation (Fig. 5 E). Importantly, when RNAi is used to pre-
vent MITF up-regulation (Fig. 5 D, lanes 4 and 8), forskolin
does not inhibit proliferation of Colo829 and WM266-4 cells
(Fig. 5 E), clearly demonstrating that elevated MITF protein
levels are growth inhibitory to melanoma cells.
Our data suggest that high levels of MITF hinder cell cy-
cle progression, and it has been suggested that MITF-induced
cell cycle exit is necessary for melanocyte differentiation
(Loercher et al., 2005). Consistent with this, melanogenesis-
inducing factors such as 
 
 
 
–melanocyte-stimulating hormone
and forskolin, which up-regulate MITF expression (Bertolotto
et al., 1998), also block melanoma cell proliferation. More-
over, MITF regulates transcription of the cell cycle inhibitors
p16
 
Ink4a
 
 and p21
 
Cip1
 
 (Carreira et al., 2005; Loercher et al.,
2005). However, Colo829 and WM266-4 cells are p16
 
Ink4a
 
negative (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200505059/DC1), and we did not observe increased
p21 expression in response to forskolin (not depicted), sug-
Figure 4.
V600EB-RAF activates ERK and suppresses MITF expression in
human melanocytes. (A) Western blot analysis of ppERK and ERK2 in
primary human melanocytes (NHM) that were untreated or treated with
10  M U0126 for 24 h or with DMSO control (second lane). (B) Thymi-
dine incorporation into NHM treated with 10  M U0126 for 24 h,
DMSO, or no treatment control in the presence of melanocyte growth fac-
tor supplement. (C) Western blot analysis of A-RAF, B-RAF, C-RAF, ppERK,
and ERK2 in NHM transfected with either scrambled control siRNA (sc) or
siRNAs specific for A-RAF, B-RAF, or C-RAF. (D) Thymidine incorporation
into NHM in the presence of melanocyte growth factor supplement 72 h
after transfection with the indicated siRNAs. Error bars represent SD. (E)
Western blot analysis for myc-tagged B-RAF, ppERK, and ERK2 in NHM
transiently expressing either myc-
V600EB-RAF or myc-
WTB-RAF. B-RAF was re-
vealed using the antibody 9E10. (F) Immunofluorescence analysis of
transiently expressed myc-
V600EB-RAF and myc-
WTB-RAF and of endogenous
MITF in NHM transfected with myc-
V600EB-RAF or myc-
WTB-RAF. B-RAF pro-
teins are revealed with anti-myc, and MITF is revealed with C5. Nuclei are
counterstained with DAPI. Arrows indicate nuclei of transfected cells ex-
pressing either wild-type B-RAF or mutant 
V600EB-RAF. (G) Quantification of
immunofluorescence data. Means of three experiments are shown (100
cells were counted in each experiment). Vector-transfected cells served as
a control.
Figure 5. Enhanced MITF expression contributes to cAMP-induced growth
inhibition of melanoma cells. (A) Western blot analysis of endogenous
MITF, ppERK, and ERK2 in melanoma cell lines expressing oncogenic RAS
or B-RAF compared with NHM. MITF was revealed using anti-MITF (D5).
(B) Western blot of endogenous MITF (using antibody D5) and ERK2 as a
loading control in NHM treated with 20  M forskolin or DMSO for the
indicated times in the absence of melanocyte growth factor supplement.
(C) Thymidine incorporation into NHM in the absence of melanocyte
growth factor supplement after 20  M forskolin treatment for 24 h or
DMSO treatment. (D) Western blot analysis of MITF (D5) and ERK2 in un-
treated or 20  M forskolin-treated (16 h) Colo826 or WM266-4 cells in
the presence or absence of either MITF-specific siRNA or scrambled con-
trol (sc). (E) Thymidine incorporation in parallel samples from D. Thymi-
dine incorporation in DMSO-treated cells was set at 100%. Results are
from triplicate assays with error bars to represent SD from the mean. 
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gesting that MITF inhibits growth through alternative mecha-
nisms in these cells.
The antiproliferative effects of high MITF levels in human
melanoma is supported by the fact that MITF mRNA expression
is frequently low or undetectable in human melanoma cells
(Vachtenheim and Novotna, 1999). Importantly, MITF reex-
pression in transformed MITF-negative human melanocytes
and melanoma cells reduces their tumorigenecity in vivo
(Selzer et al., 2002), suggesting that elevated MITF is incom-
patible with melanoma progression. Notably, low MITF levels
are linked to reduced survival rates and increased metastases
in patients with intermediate thickness melanoma (Salti et
al., 2000). Furthermore, MITF target genes such as melan-a/
MART-1 or melastatin/TRPM1 are generally down-regulated in
more advanced melanomas (Duncan et al., 1998; Hofbauer et
al., 1998), which is consistent with MITF not being expressed
or being nonfunctional. Our data have clear clinical implica-
tions, suggesting that MITF has important prognostic value in
melanoma, particularly if used in conjunction with B-RAF mu-
tation status, which is an area that needs urgent investigation.
Previous studies have suggested that MITF protein levels
are regulated by ERK-induced degradation (Wu et al., 2000;
Xu et al., 2000) and, in agreement with this, we observe that
MITF expression is significantly reduced in melanocytes in
which ERK is constitutively active as a result of oncogenic
B-RAF expression. However, we note that in melanoma cell
lines and clinical samples of melanoma, MITF expression is
not completely suppressed. We propose that MITF function
cannot be completely abolished in melanoma and that low level
expression must be maintained to stimulate survival and/or
proliferation, possibly by regulating BCL2 (McGill et al.,
2002) and CDK2 (Du et al., 2004) expression. Presumably,
mechanisms exist to counteract the suppression of MITF ex-
pression by oncogenic B-RAF such as maintaining its expres-
sion at a level that is compatible with tumor progression but
insufficient to suppress cell growth. We are currently devel-
oping genetic approaches to test this hypothesis. Our data
demonstrate that MITF expression is carefully regulated in
melanocytes and melanoma cells and that the regulation of its
expression by oncogenic B-RAF warrants further study.
 
Materials and methods
 
Cell culture and transfection
 
Melan-a cells expressing B-RAF, 
 
V600E
 
B-RAF, MEK
 
EE
 
, and 
 
G12V
 
RAS were de-
scribed previously (Wellbrock et al., 2004b). Melan-a cells (gift of D. Ben-
nett, St. George’s Hospital Medical School, London, UK) and melan-a–B-RAF
cells were grown in RPMI/10% FCS supplemented with 200 nM TPA and
120 pM cholera toxin. Melan-a–VE and melan-a–VE-derived cells were cul-
tured in RPMI/10% FCS. Melan-a–VE/ER-MITF cells expressed MITF that was
fused to the ligand-binding domain of the ER (ER-MITF; gift from C. Goding,
Marie Curie Research Institute, Oxted, UK; Carreira et al., 2005), and
melan-a–VE/ER cells expressed only the ER fragment. They were created by
transfecting melan-a–VE11 cells with pRK5HA.ER or pRK5HA.ER-MITF and
1:10 of pCDNA3.1/Hygro and were selected in 0.5 mg/ml Hygromycin
for 1 wk. pRK5ER and pRK5ER-MITF were generated by cloning HA.ER
and HA.ER-MITF as EcoRI fragments from pBABEpuroHA.ER and pBA-
BEpuroHA.ER-MITF (Carreira et al., 2005) into pRK5. Human melanoma cell
lines were grown in DME/10% FCS. NHM were cultured in medium 154
with HMGS-2 (Cascade Biologics, Inc.) and transfected with 5 
 
 
 
g DNA us-
ing a Nucleofector according to the manufacturer’s protocols (Amaxa).
 
Thymidine incorporation, long-term growth, and colony formation assay
 
Cells were incubated with 0.4 
 
 
 
Ci/ml 
 
3
 
H-thymidine for 4 h before harvest-
ing and were quantified by liquid scintillation counting. For long-term
growth, melan-a–VE/ER and melan-a–VE/ER-MITF cells were seeded at
0.5 
 
  
 
10
 
6
 
 cells per 10-cm dish in 5% FCS (
 
 
 
/
 
 
 
 4-OHT), counted every 3 d,
and replated at 0.5 
 
 
 
 10
 
6
 
 cells per dish. For clonogenic survival, cells were
transfected with pCDNA3.1/V5-HisMITF (provided by H. Arnheiter, Porter
Neuroscience Research Center, Bethesda, MD) or pCDNA3.1/V5-His plus
1:10 of pCDNA3.1/Hygro and were selected in Hygromycin for 5 d. After
a further 10 d without Hygromycin, colonies were stained with crystal violet.
 
Cell lysis, Western blotting, and antibodies
 
Western blot analysis was performed by standard protocols with the fol-
lowing antibodies: A-RAF (C-20; Santa Cruz Biotechnology, Inc.), B-RAF
(F-7; Santa Cruz Biotechnology, Inc.), C-RAF (Transduction Laboratories),
phosphorylated ERK (ppERK; MAPK-YT; Sigma-Aldrich), myc tag (9E10),
HA tag (12CA5), ERK2 (C-14; Santa Cruz Biotechnology, Inc.), MITF (C5
and D5; Neomarkers and provided by D. Fisher, Dana-Farber Cancer In-
stitute, Boston, MA), rabbit anti-myc (Abcam), and phosphorylated CREB
(Cell Signaling).
 
RNAi
 
Cells were transfected as described previously (Wellbrock et al., 2004b)
using 20–120 nM A-RAF, C-RAF, scrambled (Karasarides et al., 2004),
B-RAF (5
 
 
 
-AACAGUCUACAAGGGAAAGUG-3
 
 
 
), or melanocyte-specific
MITF (5
 
 
 
-AGCAGTACCTTTCTACCAC-3
 
 
 
) siRNA oligonucleotides.
 
Luciferase assays
 
2.5 
 
 
 
 10
 
5
 
 cells were transfected with 0.6 
 
 
 
g pGL2 or pGL2htyr (Heme-
sath et al., 1998) with 0.4 
 
 
 
g pSV–
 
 
 
-galactosidase (Promega) using Li-
pofectAMINE (GIBCO BRL) and were treated with 4-OHT after 24 h for
a further 24 h before lysis in reporter lysis buffer (Promega) for luciferase
activity analysis. Experiments were performed in triplicate, and luciferase
activity was corrected for 
 
 
 
-galactosidase expression.
 
RT-PCR
 
RNA was isolated using TRIzol (GIBCO BRL), and first-strand cDNA synthesis
was performed with 1 
 
 
 
g of total RNA and random hexanucleotides. Spe-
cific genes were amplified under conditions in which amplification was still
linear. Primers that were used are listed as follows: 
 
gapdh
 
 (5
 
 
 
-CGGAGT-
CAACGGATTTGGTCGTAT-3
 
  
 
and 5
 
 
 
-AGCCTTCTCCATGGTGGTGAA-
GAC-3
 
 
 
) and melanocyte-specific 
 
mitf
 
 (5
 
 -ATGCTGCAAATGCTAGAATA-
CAGTCACTA-3  and 5 -GTTGCTGTAGAGGTCGATCAAGTTTCC-3 ).
Immunofluorescence
Cells that were grown on glass coverslips were fixed in methanol/ace-
tone, blocked with 1% BSA/PBS, and incubated with rabbit anti-myc (Ab-
cam) and/or anti-MITF (clones C5 and D5; Neomarkers). Staining was re-
vealed by using secondary antibodies that were conjugated to Cy2 or
Cy3 (Dianova), and nuclei were counterstained with DAPI. Cells were
mounted in DABCO-glycerol.
Microscopy and image analysis
Fluorescence images were acquired at RT with a 40 /0.55 long working
distance objective lens on a microscope (model TS-100; Nikon) with fluo-
rescence optics. Bright field images were acquired with a 20 /0.4 long
working distance objective lens on the same microscope. A camera
(model DN-100; Nikon) was used for image processing using Nikon ac-
quisition software.
Online supplemental material
Fig. S1 shows Western blot analysis of p16
INK-4a in melanoma cell lines
SKMel-2, A375, WM266-4, Colo829, and SKMel-28 and in NHM. ERK2
serves as a loading control. Online supplemental material is available at
http://www.jcb.org/cgi/content/full/jcb.200505059/DC1.
We thank Prof. D. Bennett for providing the melan-a cells; Dr. C. Goding for
the pCMVHA-MITF, pCMVHA-S73A-MITF, pBABEpuroHA.ER, and pBA-
BEpuroHA.MITF-ER plasmids; Dr. D. Fisher for the pGL2htyr construct and C5
MITF antibody; and Dr. H. Arnheiter for the pCDNAV5MITF plasmid. 
This work was funded by Cancer Research UK (grant C107/A3096)
and The Institute of Cancer Research. The authors have no conflicting interests
involving this work.
Submitted: 10 May 2005
Accepted: 15 July 2005JCB • VOLUME 170 • NUMBER 5 • 2005 708
References
Bertolotto, C., P. Abbe, T.J. Hemesath, K. Bille, D.E. Fisher, J.P. Ortonne, and R.
Ballotti. 1998. Microphthalmia gene product as a signal transducer in
cAMP-induced differentiation of melanocytes. J. Cell Biol. 142:827–835.
Carreira, S., J. Goodall, I. Aksan, S.A. La Rocca, M.D. Galibert, L. Denat, L.
Larue, and C.R. Goding. 2005. Mitf cooperates with Rb1 and activates
p21Cip1 expression to regulate cell cycle progression. Nature. 433:
764–769.
Davies, H., G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague,
H. Woffendin, M.J. Garnett, W. Bottomley, et al. 2002. Mutations of the
BRAF gene in human cancer. Nature. 417:949–954.
Du, J., H.R. Widlund, M.A. Horstmann, S. Ramaswamy, K. Ross, W.E. Huber,
E.K. Nishimura, T.R. Golub, and D.E. Fisher. 2004. Critical role of
CDK2 for melanoma growth linked to its melanocyte-specific transcrip-
tional regulation by MITF. Cancer Cell. 6:565–576.
Duncan, L.M., J. Deeds, J. Hunter, J. Shao, L.M. Holmgren, E.A. Woolf, R.I.
Tepper, and A.W. Shyjan. 1998. Down-regulation of the novel gene mel-
astatin correlates with potential for melanoma metastasis. Cancer Res.
58:1515–1520.
Halaban, R., M. Bohm, P. Dotto, G. Moellmann, E. Cheng, and Y. Zhang. 1996.
Growth regulatory proteins that repress differentiation markers in mela-
nocytes also downregulate the transcription factor microphthalmia. J. In-
vest. Dermatol. 106:1266–1272.
Hemesath, T.J., E.R. Price, C. Takemoto, T. Badalian, and D.E. Fisher. 1998.
MAP kinase links the transcription factor Microphthalmia to c-Kit sig-
nalling in melanocytes. Nature. 391:298–301.
Hingorani, S.R., M.A. Jacobetz, G.P. Robertson, M. Herlyn, and D.A. Tuveson.
2003. Suppression of BRAF(V599E) in human melanoma abrogates
transformation. Cancer Res. 63:5198–5202.
Hofbauer, G.F., J. Kamarashev, R. Geertsen, R. Boni, and R. Dummer. 1998.
Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embed-
ded primary and metastatic melanoma: frequency and distribution. Mela-
noma Res. 8:337–343.
Karasarides, M., A. Chiloeches, R. Hayward, D. Niculescu-Duvaz, I. Scanlon,
F. Friedlos, L. Ogilvie, D. Hedley, J. Martin, C.J. Marshall, et al. 2004.
B-RAF is a therapeutic target in melanoma. Oncogene. 23:6292–6298.
Loercher, A.E., E.M. Tank, R.B. Delston, and J.W. Harbour. 2005. MITF links
differentiation with cell cycle arrest in melanocytes by transcriptional ac-
tivation of INK4A. J. Cell Biol. 168:35–40.
McGill, G.G., M. Horstmann, H.R. Widlund, J. Du, G. Motyckova, E.K. Nish-
imura, Y.L. Lin, S. Ramaswamy, W. Avery, H.F. Ding, et al. 2002. Bcl2
regulation by the melanocyte master regulator Mitf modulates lineage
survival and melanoma cell viability. Cell. 109:707–718.
Salti, G.I., T. Manougian, M. Farolan, A. Shilkaitis, D. Majumdar, and T.K. Das
Gupta. 2000. Micropthalmia transcription factor: a new prognostic marker
in intermediate-thickness cutaneous malignant melanoma. Cancer Res.
60:5012–5016.
Selzer, E., V. Wacheck, T. Lucas, E. Heere-Ress, M. Wu, K.N. Weilbaecher, W.
Schlegel, P. Valent, F. Wrba, H. Pehamberger, et al. 2002. The melano-
cyte-specific isoform of the microphthalmia transcription factor affects
the phenotype of human melanoma. Cancer Res. 62:2098–2103.
Vachtenheim, J., and H. Novotna. 1999. Expression of genes for micro-
phthalmia isoforms, Pax3 and MSG1, in human melanomas. Cell Mol.
Biol. (Noisy-le-grand). 45:1075–1082.
Wellbrock, C., M. Karasarides, and R. Marais. 2004a. The RAF proteins take
centre stage. Nat. Rev. Mol. Cell Biol. 5:875–885.
Wellbrock, C., L. Ogilvie, D. Hedley, M. Karasarides, J. Martin, D. Niculescu-
Duvaz, C.J. Springer, and R. Marais. 2004b. V599EB-RAF is an onco-
gene in melanocytes. Cancer Res. 64:2338–2342.
Widlund, H.R., and D.E. Fisher. 2003. Microphthalamia-associated transcrip-
tion factor: a critical regulator of pigment cell development and survival.
Oncogene. 22:3035–3041.
Wu, M., T.J. Hemesath, C.M. Takemoto, M.A. Horstmann, A.G. Wells, E.R.
Price, D.Z. Fisher, and D.E. Fisher. 2000. c-Kit triggers dual phosphory-
lations, which couple activation and degradation of the essential melano-
cyte factor Mi. Genes Dev. 14:301–312.
Xu, W., L. Gong, M.M. Haddad, O. Bischof, J. Campisi, E.T. Yeh, and E.E.
Medrano. 2000. Regulation of microphthalmia-associated transcription
factor MITF protein levels by association with the ubiquitin-conjugating
enzyme hUBC9. Exp. Cell Res. 255:135–143.